Abstract: An in vitro method for the prognosis or prediction of response in patients with rheumatoid arthritis to treatment with agents recognising the B-lymphocyte CD20 membrane receptor. The method of the invention comprises an assay in a blood sample from these patients and measuring, before starting the treatment, the transcriptional expression level (mRNA) of at least one of the genes selected from the group: ARG1, CPD, TRAF1, C1QA, LRRN3, LRRN3, HLA-DQA1, NLK, TLR4, LOC89944, TOM1L1, BACH, NCALD, EIF2C2, NFIC, PCDHB7, FLJ32770, ARID3A, C14ORF9, CSNK1E, BCAS1, TEAD2, C6orf145 and SNTA1; and the comparison of this expression level to the expression values previously obtained in patients who responded and who did not respond to the treatment.

Abstract: The present invention provides methods for differentially diagnosing rheumatoid arthritis (RA) versus psoriatic arthritis (PsA) in an individual. Specifically, the method relates to detecting the presence or absence of distinct alleles of the PDE4D and PDE4B genes which are associated with either RA or PsA. Also provided herein are methods for selecting an individual who should receive or who is likely to respond to a treatment with a PDE4 inhibitor. The present invention also provides methods for treating an individual with RA or PsA.

Abstract: The present invention provides methods for selecting an individual with psoriasis (Ps) or psoriatic arthritis (PsA) who should receive or who is likely to respond to a treatment with an anti-tumor necrosis factor alpha (anti-TNF?) therapy. In addition, provided herein are methods for selecting an individual with Ps or PsA who should receive or who is likely to respond to a therapy that is not an anti-TNF? therapy, e.g., a non-anti-TNF? therapy for the treatment of Ps or PsA. Specifically, the methods of the present invention relate to detecting the presence of distinct alleles of the PDE3A-SLCO1C1 locus which are associated with a clinical response to an anti-TNF? therapy or a non-anti-TNF therapy in patients with Ps or PsA.

Abstract: This invention provides methods for predicting response to anti-TNF? biological agent treatment in a rheumatoid arthritis patient and methods for selecting a treatment for a rheumatoid arthritis patient, the methods comprising determining the level of expression of PIK3CD as a biomarker, and optionally also determining the level of expression of CX3CL1 as a second biomarker. The invention additionally provides kits for carrying out the methods described.

Abstract: Provided herein are methods for predicting a response to anti-TNF? biologic treatment in patients suffering from rheumatoid arthritis (RA). The methods can be used to discriminate or categorize patients as likely to respond to a monoclonal antibody-based anti-TNF? biological inhibitor, but not likely to respond to an antibody fragment-based anti-TNF? biological inhibitor or a TNF receptor-based biological inhibitor. Alternatively, the methods are also useful to determine whether patients with RA are likely to respond to an antibody fragment-based anti-TNF? biological inhibitor or a TNF receptor-based biological inhibitor, but not likely to respond to a monoclonal antibody-based anti-TNF? biological inhibitor. Also provided are methods for treating a patient with RA based on the patient's level of rheumatoid factor (RF) and/or anti-cyclic citrullinated peptide autoantibody (ACPA) relative to reference control levels.

Abstract: In vitro method and kit for prognosis or prediction of the response of rheumatoid patients to treatment with TNF-? factor blocking agents, which comprises determining, in a blood sample from said patients, the expression level of at least one of the eight genes selected from the group: HLA-DRB3, EAT2, GNLY, CAMP, SLC2A3, IL2RB, MXD4 and TLR5 or combinations thereof and comparing said expression level to the expression values obtained from responsive and non-responsive patients who showed responsiveness to the treatment and those who showed non-responsiveness thereto.

Abstract: An in vitro method for the prognosis or prediction of response in patients with rheumatoid arthritis to treatment with agents recognising the B-lymphocyte CD20 membrane receptor. The method of the invention comprises an assay in a blood sample from these patients and measuring, before starting the treatment, the transcriptional expression level (mRNA) of at least one of the genes selected from the group: ARG1, CPD, TRAF1, C1QA, LRRN3, HLA-DQA1, NLK, TLR4, LOC89944, TOM1L1, BACH, NCALD, EIF2C2, NFIC, PCDHB7, FLJ32770, ARID3A, C14ORF9, CSNK1E, BCAS1, TEAD2, C6orfl45 and SNTA1; and the comparison of this expression level to the expression values previously obtained in patients who responded and who did not respond to the treatment.

Abstract: In vitro method and kit for prognosis or prediction of the response of rheumatoid patients to treatment with TNF-? factor blocking agents, which comprises determining, in a blood sample from said patients, the expression level of at least one of the eight genes selected from the group: HLA-DRB3, EAT2, GNLY, CAMP, SLC2A3, IL2RB, MXD4 and TLR5 or combinations thereof and comparing said expression level to the expression values obtained from responsive and non-responsive patients who showed responsiveness to the treatment and those who showed non-responsiveness thereto.